Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0035-9203(82)90128-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trustworthy AI: responses to commentators.
Asian J Philos
December 2024
COGITO Epistemology Research Centre, University of Glasgow, 67-69 Oakfield Ave, Glasgow, G12 8LP UK.
In 'Trustworthy Artificial Intelligence', we develop a novel account of how it is that AI can be trustworthy and what it takes for an AI to be trustworthy. In this paper, we respond to a suite of recent comments on this account, due to J. Adam Carter, Dong-yong Choi, Rune Nyrup, and Fei Song.
View Article and Find Full Text PDFTackling algorithmic bias and promoting transparency in health datasets: the STANDING Together consensus recommendations.
Lancet Digit Health
January 2025
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK; Centre for Patient Reported Outcomes Research, School of Health Sciences, College of Medical and Dental Sciences, Birmingham, UK; University of Birmingham, Birmingham, UK. Electronic address:
Article Synopsis
- There is a significant risk of reinforcing existing health inequalities in AI health technologies due to biases, primarily stemming from the datasets used.
- The STANDING Together recommendations focus on transparency in health datasets and proactive evaluation of their impacts on different population groups, informed by a comprehensive research process with over 350 global contributors.
- The 29 recommendations are divided into guidance for documenting health datasets and strategies for using them, aiming to identify and reduce algorithmic biases while promoting awareness of the inherent limitations in all datasets.
Post-extubation using high nCPAP: are we ready for the change?
Transl Pediatr
November 2024
Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, USA.
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Gynecol Oncol
November 2024
Department of Oncology, Rigshopitalet, Copenhagen University Hospital, Copenhagen, and Nordic Society of Gynaecological Oncology-Clinical Trial Unit, Copenhagen, Denmark.
Objectives: Part 1 of the RUBY trial (NCT03981796) demonstrated improved survival in patients with primary advanced or recurrent endometrial cancer (EC) treated with dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel. Here, we examine additional efficacy and safety data from patients with mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) EC in the RUBY trial.
Methods: Patients were randomized 1:1 to dostarlimab 500 mg or placebo plus carboplatin-paclitaxel every 3 weeks for 6 cycles followed by dostarlimab or placebo every 6 weeks for up to 3 years.
Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical Trial.
JAMA
December 2024
Kidz First Neonatal Care, Te Whatu Ora Counties Manukau, Auckland, New Zealand.
Article Synopsis
- Bronchopulmonary dysplasia (BPD) is a serious condition affecting extremely preterm infants, and while systemic corticosteroids can help, they come with risks; inhaled corticosteroids may provide a safer alternative.
- The study aimed to assess the effectiveness of administering budesonide, an inhaled corticosteroid, alongside surfactant in improving survival rates without BPD among extremely preterm infants.
- Conducted across 21 neonatal units in four countries, the trial involved 1,059 infants and found that 25.6% of those receiving budesonide plus surfactant survived without BPD, compared to 22.6% in the surfactant-only group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!